Combined treatment with artesunate and bromocriptine has synergistic anticancer effects in pituitary adenoma cell lines

Oncotarget
Xin WangYonghong Zhu

Abstract

Prolactinomas are the most prevalent functional pituitary adenomas. The preferred treatments for prolactinomas are dopamine agonists (DAs) such as bromocriptine (BRC), but DAs still have the challenges of tumor recurrence and drug resistance. This study demonstrates that the synergy of function and mechanism between artesunate (ART) and BRC inhibits prolactinoma cell growth in vitro. We found that low-dose ART combined with BRC synergistically inhibited the growth of GH3 and MMQ cell lines, caused cell death, attenuated cell migration and invasion, and suppressed the expression of extracellular prolactin. The induction of apoptosis after co-treatment was confirmed by immunofluorescent staining, assessment of caspase-3 protein expression, and flow cytometry. Expression of miR-200c, a carcinogenic factor in pituitary adenoma, was reduced following co-treatment with ART and BRC. This was accompanied by increased expression of the antitumor factor Pten. Transfection experiments with miR-200c analogs and inhibitors confirmed that miR-200c expression was inversely associated with Pten expression. We suggest that ART and BRC used in combination exert synergistic apoptotic and antitumor effects by suppressing miR-200c and stimulating P...Continue Reading

References

Oct 23, 2002·Cardiology in Review·Jacques SerratricePierre-Jean Weiller
Dec 14, 2002·Mayo Clinic Proceedings·Allison M PritchettRaul E Espinosa
Oct 25, 2003·Oncogene·Gary D Kruh
Nov 25, 2003·The New England Journal of Medicine·Annamaria ColaoGaetano Lombardi
Jul 27, 2004·Cancer·Shereen EzzatIan E McCutcheon
Jun 11, 2005·Endocrine-related Cancer·M MusatA B Grossman
Dec 6, 2005·Pituitary·Patricia Fainstein DayMallea Gil
Jan 18, 2006·Pituitary·Mark E Molitch
Dec 5, 2006·Journal of Clinical Pathology·N Y Y Al-Brahim, S L Asa
Mar 8, 2007·Carcinogenesis·Carmen Blanco-AparicioAmancio Carnero
Apr 19, 2008·Science·N J White
Feb 12, 2009·The Journal of Clinical Endocrinology and Metabolism·S MelmedUNKNOWN Acromegaly Consensus Group
Apr 2, 2009·The Journal of Clinical Endocrinology and Metabolism·J KharlipG S Wand
Apr 30, 2009·Annual Review of Pathology·Sylvia L Asa, Shereen Ezzat
Jun 6, 2009·The Journal of Clinical Endocrinology and Metabolism·M KarsO M Dekkers
Jul 25, 2009·Cell Cycle·Maria T Diaz-Meco, Shadi Abu-Baker
Nov 3, 2009·The Journal of Clinical Endocrinology and Metabolism·Olaf M DekkersAlberto M Pereira
Apr 6, 2011·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Sylvia L Asa
Jan 1, 2006·CSH Protocols·Joseph Sambrook, David W Russell
Jul 7, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Heejeong LeeChul Soo Park
Sep 24, 2015·Oncotarget·Cailu SongXiaoming Xie

❮ Previous
Next ❯

Methods Mentioned

BETA
fluorescence-activated cell sorting
flow cytometry
FACS
ELISA
PCR
transfection
Assay
protein assay
electrophoresis

Software Mentioned

Image Pro - plus
ImageJ
SPSS
Primer
BLAST

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.